Figures below are as of 21 Jul 2026. GMP is an unofficial, unregulated indicator of grey-market demand and is not investment advice.
| Grey Market Premium (GMP) | ₹145 |
| Estimated listing gain | +69.7% |
| Estimated listing price | ₹353 |
| Issue price | ₹208 |
| Issue size | ₹30.24 Cr |
| Subscription | 385.32x |
| Open date | 18 Jun 2026 |
| Close date | 22 Jun 2026 |
| Listing date | 25 Jun 2026 |
| Listing at | NSE SME |
| IPO type | SME |
| Registrar | Skyline Financial Services Pvt.Ltd. |
As of 21 Jul 2026, the grey market premium (GMP) for the Avience Biomedicals Ltd. IPO is ₹145, implying an estimated listing gain of about +69.7% and an estimated listing price near ₹353. GMP is unofficial and unregulated — it indicates grey-market sentiment, not a guaranteed listing price.
The Avience Biomedicals Ltd. IPO is open for subscription from 18 Jun 2026 to 22 Jun 2026. It is expected to list on 25 Jun 2026.
The Avience Biomedicals Ltd. IPO is priced at ₹208 per share, with a total issue size of ₹30.24 Cr.
As of 21 Jul 2026, the Avience Biomedicals Ltd. IPO is subscribed 385.32x.